ALEXA HAMMOCK: Open Payments
NPI 1851152409 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,779 in 116 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $1,784 · 2025 $1,779
Food & beverage: $1,779
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $401 |
| Lilly USA, LLC | 11 | $205 |
| Novo Nordisk Inc | 14 | $194 |
| PFIZER INC. | 12 | $159 |
| AstraZeneca Pharmaceuticals LP | 7 | $147 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $139 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $45 |
Products named: QULIPTA, CAPLYTA, XIFAXAN, VRAYLAR, MOUNJARO, Ozempic, UBRELVY, NURTEC ODT.
Industry payments across VA — which companies pay providers there.
